MedPath

Effect of Systemic Isotretinoin on Serum Irisin Level in Acne Vulgaris Patients

Not Applicable
Completed
Conditions
Acne Vulgaris
Interventions
Registration Number
NCT05869188
Lead Sponsor
South Valley University
Brief Summary

Acne vulgaris is a chronic inflammatory skin disease affecting the pilosebaceous unit. It is clinically characterized by comedones, papules, pustules, nodules, cysts and scarring on the face and trunk.

The severity of the disease ranges from mild comedonal acne to severe nodulocystic acne which can be permanently disfiguring.In addition to the physical lesions, the disease can have a profound psychologic impact, contributing to low self-esteem, depression and anxiety.In addition to the physical lesions, the disease can have a profound psychologic impact, contributing to low self-esteem, depression and anxiety.

Detailed Description

The prevalence of self-reported acne and clinically confirmed acne was 34.69% and 24.39%, respectively. Females reported acne more frequently than males did (39.13% ).The prevalence of clinically confirmed acne was higher among females (28.64%) than males .

Its pathogenesis results from androgen-induced increased sebum production, altered keratinization, inflammation of infundibular epithelium and bacterial colonisation of hair follicles by Propionibacterium acne

There are several treatment modalities for acne vulgaris including topical like topical antibiotics, topical benzoyl peroxide, topical azelaic acid and topical retinoids. Systemic therapy like antibiotics, hormonal therapy and isotretinoin .

Adipokines may have a role in the pathogenesis of acne vulgaris and are associated with acne severity. Irisin, a hormone -like myokine, is one of the adipokines with anti- inflammatory and anti-oxidant effects

There is limited evidence for physical modalities (e.g., laser therapy, light therapy, chemical peels) and complementary therapies (e.g., purified bee venom, low-glycemic-load diet, tea tree oil) .

isotretinoin (13-cis retinoic acid) is the most potent known inhibitor of sebum production. The multiple modes of action for isotretinoin includs suppression of sebaceous gland activity, normalization of the pattern of keratinization within the sebaceous gland follicle, inhibition of inflammation and reduction of growth of Propionibacterium acne .

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Cases with moderate and severe acne.
  • Clinical diagnosis of acne Disease
  • Patient not receive any treatment for acne vulgaris at least six months duration.
Exclusion Criteria

1 Pregnant and lactating women. 2. History of chronic liver disease . 3. Cardiovascular disorders . 4. Renal disease . 5. Hyperlipidemia . 6. Depression or mental illness. 7. Insulin dependent diabetes 8 Thyroid disease. 9 Osteoporosis or low bone mineral density . 10 Intestinal disorders such as inflammatory bowel disease or ulcerative colitis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Pateints with Moderate AcneIsotretinoin20 patients affected by Acne and More than half of the face is involved. Many papules and pustules, many open or closed comedones. One nodule may be present.
controlIsotretinoin20 Health participants
Pateints with Severe AcneIsotretinoin20 patients affected by Acne and Entire face is involved, covered with many papules and pustules, open or closed comedones and rare nodules
Primary Outcome Measures
NameTimeMethod
Evalaute serum level of irisin in acne patientFrom 0 base to 3 Months from starting the treatment Day

Assessment of clinical improvement according to:(8) G4(excellent:100% reduction) G3(good:75-99% reduction) G2(moderate: 50-74% reduction) G1(insufficient :1-49% reduction) G0(unchanged) G-1(worse)

Secondary Outcome Measures
NameTimeMethod
Evalaute the effect of treatment with systemic isotretinonFrom 0 base to 3 Months from starting the treatment Day

Evalaute the effect of treatment with systemic isotretinon on the level of serum irisin .

Trial Locations

Locations (1)

Qena Hospital

🇪🇬

Qinā, Egypt

© Copyright 2025. All Rights Reserved by MedPath